We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

3,500
Open access books available

108,000
International authors and editors

1.7 M
Downloads

151
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us? Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected. For more information visit www.intechopen.com
1. Introduction

In many countries Type 1 diabetes [T1D] is the most common life-threatening disease in children, and nobody can be cured. For long time the incidence has increased all over the world [1]. The disease causes serious morbidity and increased mortality [2,3] in spite of an intensive treatment with multiple daily injections of insulin, adapted to regular meals with suitable content based on self-monitoring of blood glucose. Many patients do never succeed to get good metabolic control because of the complicated treatment and another problem preventing good metabolic control is hypoglycaemia [4]. Modern insulin pumps and glucose sensors have made it possible to improve insulin treatment [5]. The simplest approach to reduce severity of hypoglycaemia when treatment is intensified is to interrupt insulin delivery. There are insulin pumps with an integrated continuous glucose monitoring, which automatically suspends insulin delivery for up to 2 hours when hypoglycaemia is detected even when the hypoglycaemia alarm is not acknowledged by the patient [6,7]. Closed-loop insulin delivery [artificial pancreas] is aiming to achieve near normal blood glucose without increasing the risk of hypoglycaemia [8]. Thus a disposable sensor measures interstitial glucose levels, which are fed into an algorithm controlling delivery of a rapid-acting insulin analog into the subcutaneous tissue by an insulin pump. So far research has focused on closed loop insulin delivery during night, and this technique is improving [9]. However, also in the future there will be need for the patient to learn how to handle also these devices, not least during infections, longer exercise, and several other situations and changes of life.

2. Introduction

Even though patients with T1D need insulin, the primary goal of novel therapies is to preserve residual insulin secretion, in best case to cure diabetes or at least to make the disease milder.
and facilitate treatment. Patients with residual insulin secretion usually get lower HbA1c, and residual insulin secretion facilitates the treatment, decreases the risk for serious hypoglycaemia and the risk of keto-acidosis [10]. Already very modest beta cell function, with peak stimulated C-peptide above 0.2 nmol/L seems to reduce long-term complications [11]. Furthermore, C-peptide per se has been proposed to decrease the risk of complications, especially neuropathy. There is increasing evidence that C-peptide is not just a connecting peptide to keep the two insulin chains in in a certain structure, but a hormone with several important effects [12]. The relevance of saving beta cells and improving their function has become even more evident when studies suggest that beta cells may regenerate [13, 14]. If this is the case an end of the destructive process might lead to cure of TID [15].

3. The immunological disease process

The generally accepted opinion is that the majority of the pancreatic beta cells are lost at the diagnosis of Type 1 diabetes. The beta cells are supposed to be killed by an autoimmune process precipitated and promoted by genetic and environmental factors. In recent years the dogma saying that most beta cells are dead has been questioned, and regeneration of the beta cells seems not only possible but quite plausible. Actually that was discussed as a possibility already several decades ago (Fig 1). Thus, many beta cells may still be living in pancreas although they do not respond normally to stimulus with insulin secretion. Auto-antibodies are usually found, but regarded as markers of the process, rather than causing beta cell death. The auto-antibodies react against the islet cells (Islet Cell Antibodies; ICA) [16] or against specific auto-antigens such as Insulin Auto-antibodies against Insulin (IAA) [17], against Glutamic Acid Decarboxylase (GADA) [18], against Tyrosin Phosphatase (IA-2A) [19] or against ZincTransport Antigen (ZnTA) [20]. These antigens are attacked by the own immune system. Dysregulation of the immune system is thought to allow a self-destructive process. Mononuclear cells, mainly T-cells, seem to play the most important role for the killing of the beta cells.

4. Immune interventions

Several immune interventions have been tried since the 1970ies we tried plasmapheresis in Linköping, Sweden, with the aim to preserve residual beta cell function, but so far all different approaches have shown insufficient efficacy and/or given unacceptable adverse effects [21-28]. Broad immunosuppressive or immunoblocking therapies with steroids, cytostatics, high doses of immunoglobulins, anti-lymphocyte globulins have shown some but unfortunately limited efficacy, and adverse events have lead to restrictions both in dose and time. Our studies using photopheresis did show some efficacy, and although the treatment was very laborious it has regained some interest. However, most encouraging is the use of monoclonal antibodies, especially against CD-3 [29-31] but also against CD-20 [32]. Unfortunately treatment with monoclonal antibodies in doses large enough to give efficacy also cause rather common and occasionally serious adverse events. Therefore such therapies are rarely justified as preventive...
interventions in healthy children with increased risk of developing T1D except for children with extremely high risk of developing T1D close in time.

Figure 1. At a Nordic symposium in connection with Annual meeting of Scandinavian Society for the Study of Diabetes, Linköping 1981, the author showed this slide. Type 1 diabetes was proposed to develop after a long autoimmune process destroying the beta cells. Events during pregnancy and the importance of breast-feeding was suggested, and later shown to be relevant, and regeneration of beta cells was proposed as a possibility.

After encouraging Phase II trials two different Phase III trials using antiCD3 failed to reach their primary endpoints [33,34], but one of them, the Protégé study, did show efficacy in younger patients age 8-18 years when a reasonably high dose of antiCD-3 was used [34]. This was especially true in certain patient populations (mainly patients in USA, but also in Europe) who had rather well preserved C-peptide, often near-normal HbA1c and low insulin requirement. Further studies are needed to learn what doses are efficient without severe adverse events, and in what patient populations the treatment works best. The old policy defended by many diabetologists to treat all so called T1D in the same way irrespective of age, ethnic background, severity of disease at diagnosis etc may probably have to be left.

5. Vaccines against infections

Traditional vaccinations could either contribute to the development of T1D, or T1D could be prevented by vaccination. Already in the 1920ies mumps infection was shown to be a possible
cause of insulin dependent diabetes [35]. A general vaccination against mumps might then either decrease the incidence of TID, or vaccination with living virus might on the contrary initiate an autoimmune process leading to an increased incidence of TID. None of these associations have been proven [36, 37]. Neither have there been any associations between vaccinations against other microbes and the development of diabetes [38].

Enterovirus infections are most suspected to cause TID. Epidemiological studies have provided evidence of coxsackie virus (CVB) infections in subjects who later develop TID [39]. A CVBB4 strain E2 was isolated from pancreas of a diabetic child, and the virus was then passed into islet cells and found to cause diabetes in mice, which was taken as a proof of the concept that coxsackievirus can cause TID [40]. So far vaccination against these types of infections to preserve beta cells has been disappointing.

The hygiene hypothesis suggests that the immune system would deviate less often towards an autoimmune process if the immune system was occupied by an ongoing defence against serious enemies. In accordance with this hypothesis, Calmette vaccination has been tried to preserve beta cell function but no clinical effect has been seen [41].

6. Immune intervention by probiotics

Several findings indicate that the gut is involved in the development of the disease process leading to TID [42]. The intestinal barrier may be disturbed. This might facilitate passage of proteins which could contribute to the autoimmune process. Cows milk [43], and bovine insulin in cows milk has been suggested as a possible cause of an autoimmune reaction against insulin [44]. Maturation of the immune system may also be influenced by the gut flora. Probiotics can probably influence immune function through effects on antigen-presenting cells, regulatory T cells and effector T and B cells [45] and probiotics may prevent autoimmune diabetes in NOD mice [46,47]. However, although use of probiotics would be attractive as the adverse events can be expected to be minimal, there are so far no studies proving any effect.

7. Heat shock protein used in immune intervention

Studies in experimental animals have shown that use of a 65-kDa heat shock protein can prevent diabetes [48]. A specific peptide, Diapep 277, seems to be the active component and this peptide has been tried with interesting effects.

Clinical trials in humans have shown that sc administration of Diapep 277 may preserve beta cell function in adults [49]. Thus 35 patients with type 1 diabetes and basal C-peptide above 0.1 nmol/L were assigned to subcutaneous injections of 1 mg Diapep277 and 40 mg mannitol in vegetable oil. The primary endpoint was glucagon-stimulated C-peptide production. At 10 months, mean C-peptide concentrations had fallen in the placebo group (n=16) but were maintained in the DiaPep277 group (n=15; p=0.039). Need for exogenous insulin was higher in the
placebo than in the DiaPep277 group. There were no adverse events. The treatment of newly diagnosed T1D adults with DiaPep277 seemed to preserve residual insulin secretion through induction of a shift from Thr-1 to Thr-2 cytokines. However, the efficacy seen in adults could not be confirmed in children and adolescents with TID [50,51] in spite of interesting immunological results [52]. In a recent Phase III trial no immunological difference could be found between adults treated with Diapep 277 or those treated with placebo [53]. Treatment with Diapep 277 seemed to preserve C-peptide but only C-peptide after Glucagon stimulation, but not after Mixed Meal Tolerance Test [54]. Thus it is still unclear whether Diapep 277 has a place or not as future intervention to preserve residual insulin secretion in adults.

8. “Inverse vaccination “to reduce the immune response

Traditional vaccination is strengthening the immune reaction against an antigen, usually an infectious microbe. Methods of reducing a pathological specific immune response e.g. in autoimmune diseases like TID can be regarded as a sort of “inverse” vaccination. In allergy tolerance against the allergens is created by presenting the antigen/allergen/s in gradually increasing doses. Such Immunotherapy has become quite efficacious [55] and the adverse events are rare.

It would be reasonable to try to reduce an autoimmune process in an analogue way, by administration of auto-antigen/s. Thus, instead of suppressing the immune system, the immune response should be modulated by presenting antigen/s in a way that the immune system shifts from a destructive process to tolerance [56].

If self-reactive T-cells directed against auto-antigens cause some cases of Type 1 diabetes a major question is why such self-reactive T-cells occur. Two mechanisms seem to be necessary for self-tolerance: Clonal deletion of self-reactive T-cells issued from the random recombination of genes (negative selection), and generation of self-antigen-specific natural regulatory T-cells (Tregs) which can inactivate self-reactive T-cells in the periphery when they have escaped intra-thymic negative selection [57]. In TID auto-reactivity against insulin is a common and early phenomenon. The important role of thymic insulin for development of self-tolerance has been demonstrated in transgenic mice [58], but there is still no technique to use this knowledge in clinical practice.

9. Auto-antigen treatment

9.1. “Vaccination” with insulin

Proinsulin and insulin and its different chains are so far the only known auto-antigens that are specific for the beta cells. Insulin has been used in trials to prevent diabetes among first degree relatives with increased risk of T1D. In Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) human ultralente insulin of 0.25 units x kg/day, or placebo, was given to subjects with >50%
5-year risk of getting TID. To give such large doses of insulin sc every day can not be regarded as immune intervention, but rather as beta cell support. In any case this type of treatment failed to reach the end-point [59].

Oral insulin is not supposed to be absorbed enough to affect blood glucose or to support remaining beta cells, but such an administration can be regarded as immune intervention. The DPT-1 trial randomized 372 relatives of subjects with TID, positive for IAA and with normal intravenous and oral glucose tolerance test (IVGTTs and OGTTs), to oral insulin 7.5 mg daily or placebo. Although the result was negative when comparing the groups with the pre-specified inclusion criteria, subanalyses suggested that Type 1 diabetes was significantly delayed in those individuals who had higher concentrations of IAA [60]. This suggests that auto-antigen therapy may be most efficaceous in patients whose immune system reacts strongly against a certain antigen.

The first diabetes-related auto-antibodies in young children are usually IAA and therefore insulin has been tried to prevent diabetes in high risk individuals. Intranasal proinsulin had effect in experimental animals [61] but intranasal administration of insulin in high risk children had no effect [62]. Administration of the insulin B-chain can prevent diabetes in experimental animals [63]. A combination of the insulin B-chain fragment with Freunds adjuvant has been tried also in newly-diagnosed TID adults [64]. There was effect on T-regulatory cells but no significant effect on C-peptide.

9.2. GAD-vaccination

During our studies with plasmapheresis [21] we discovered a new diabetes-related antigen, 64kD [65], which later on was found to be glutamic acid decarboxylase (GAD) [66]. Auto-antibodies towards GAD are common in TID and there are convincing results from studies of experimental animals that treatment with GAD can prevent autoimmune diabetes [67, 68].

An adjuvanted formulation, based on Alhydrogel®, a product of Aluminum hydroxide (alum), was developed to provide a drug (Diamyd®) used for evaluation in clinical trials. Alhydrogel® is used as adjuvant in vaccines for children eg DTP, Pneumococcal conjugate, Hepatitis B, Hepatitis A vaccines. Aluminum salts are inducing a humoral (Th2) rather than cellular immune response. As the TID autoimmune process is deviated towards Th1 (or cellular) response to autoantigens, alum is used to counteract this deviation and “steer” the response induced by GAD away towards a Th2 response. Inclusion of adjuvant is also a way to minimize the quantity of antigen required for treatment.

Diamyd® preclinical safety studies were done and caused no concerns for clinical safety. Evaluation of the effects of Diamyd® in several different animal models of autoimmune disease did not indicate any undesirable effects on the immune system. Phase 1 studies in humans were performed 1999. A randomized, double-blind and placebo-controlled dose-finding Phase IIa study in 47 LADA demonstrated efficacy in beta cell preservation in the 20-µg group [60]. There were no Serious Adverse Events (SAEs) and even though the number of patients was very small, this result was encouraging. Follow-up after five years completed 2008 still showed
a significantly beneficial effect of the 20μg dose of Diamyd®, and there had been very few AE, none of them considered to be treatment related [70]

A Phase IIb, randomized, double-blind, placebo-controlled multicenter Diamyd® study in 160 LADA-subjects was then performed in Sweden. Subjects received 20 μg of GAD65 or placebo on 2 occasions 4 weeks apart. The trial had a main study period of 18 months and was scheduled for unblinding in June 2007. Unfortunately, the study had to be invalidated due to concerns regarding the labeling process of the investigational product. No safety concerns were raised and no SAEs had been observed during 30 months observation.

9.3. GAD vaccination in children and adolescents

To investigate safety and efficacy of Diamyd® in T1D, a Phase II clinical trial in 70 recently diagnosed T1D children and adolescents was performed [71]. The study was a randomized, double-blind, placebo-controlled multicenter study using the same dose regimen as in the successful group of the previous LADA trial. The main study period of 15 months was completed and the trial partly unblinded for sponsor and statistician but continued blinded for all other investigators for another 15 month follow-up. Outcomes from this study provided support for clinical safety and efficacy after administration of Diamyd®. The treatment was very well tolerated and there were no treatment-related adverse events reported still after more than 4 years follow-up. Both treatment groups showed a gradual decline from baseline of both fasting and stimulated C-peptide secretion. There was no significant effect of treatment on change in fasting C-peptide after 15 months (primary endpoint). However, there was a significant efficacy seen on change in fasting C-peptide after 30 months (p=0.045), which remained significant when change in C-peptide/plasma glucose ratio was taken into account (p=0.02). Furthermore, stimulated C-peptide secretion, as measured by area under the curve (AUC), decreased significantly less in the GAD-alum treated group compared to the placebo group, both after 15 months (p=0.01) and after 30 months (p=0.04). The significant effect of treatment as change in fasting and stimulated C-peptide at month 30 remained when adjusting for duration of diabetes, age, gender, and baseline GADA levels.

However, although the c-peptide preservation was evident the insulin requirement in both treatment groups increased in the course of the study, and HbA1c, and plasma glucose levels increased during the study. HbA1c did not differ between the groups.

Duration of diabetes was very important for the efficacy of treatment (p=0.05 for fasting at month 30 and p=0.03 for stimulated C-peptide area under the curve at month 15 and 30). In patients treated within 6 months of diagnosis both fasting and stimulated C-peptide secretion (AUC), decreased significantly less in the GAD-alum treated group as compared to the placebo group over 30 months (fasting, p=0.03, and stimulated p=0.04) while no such difference was seen in patients with a longer duration of diabetes (Fig 2). The treatment effect in the short duration was still seen after more than 4 years follow-up [72] in patients with < 6 months duration of diabetes at treatment. There were no treatment-related adverse events.
Mean changes from baseline in fasting (panel A) and stimulating (Panel B) C-peptide are given for all patients included in intention to treat analyses in the group receiving the recombinant human 65-kD isoform of glutamic acid decarboxylase in a standard vaccine formulation with alum (GAD-alum; 35 patients) and in the group receiving placebo (34 patients). Mean changes from baseline in fasting (Panel C) and stimulated (Panel E) C-peptide levels are also shown for those patients treated less than 6 months after receiving the diagnosis of diabetes (11 patients in GAD-alum group and 14 patients in the placebo group). Finally, mean changes from baseline in fasting (Panel D) and stimulated (Panel F) C-peptide levels are shown for those treated 6 months or more after diagnosis (24 patients in the GAD-alum group and 20 patients in the placebo group). Stimulated C-peptide level was measured on the basis of areas under the curve in response to the mixed-meal tolerance test. I bars indicate standard errors. To convert values for C-peptide to nanograms per millimeter, divide by 0.33.

Figure 2. Mean Changes from Baseline Levels of Fasting and Stimulating C-Peptide, According to Treatment Group and Time of Treatment Relative to Diagnosis.

The Phase II trial was followed by a Phase III trial in Europe. 334 patients age 10-20 years were included, with diabetes duration <3 months at screening, fasting C-peptide >0.1 nmol/l and
pos GADA. In this study the two arms of the Phase II study (placebo resp. 20 µg of GAD65 (Diamyd®) with 30 days interval, were the same, but in addition there was a third arm where the patients got 20 µg of GAD65 (Diamyd®) sc also at Day 90 and 270 when the patients in the other arms got placebo injections. The primary endpoint was difference in C-peptide AUC after a Mixed Meal Tolerance Test. Surprisingly the study failed! [73]. The difference in AUC was only 16-18 % between the actively treated patients and the placebo group ( p= 0.10) and the difference in fasting C-peptide was similar ( p= 0.07). However, in several prespecified subgroups the efficacy was quite pronounced (around 30-40%), and significant. When combining Phase II and that arm in Phase III in which the patients received 2 doses of GAD-alum, then the efficacy measured both as fasting C-peptide and AUC after MMTT seems quite impressive after 30 months.

The question arises why the results in Phase III was so much weaker than in Phase II. There are some possible explanations: In Phase III the patients who received active drug by chance were more often 10-11 years old whereas patients in the placebo group more frequently were 16-20 years old than in the actively treated arms. It is well known that younger patients lose their residual insulin secretion more rapidly and therefore this difference in ages might have influenced the result. There are also other facts which may have played a role. Thus, in the Phase II trial the patients were treated in March–April and when looking at patients in Phase III who were treated in March–April there was in fact also significant effect of GAD-treatment. Finally, in the Phase II trial no vaccinations were accepted, but in Phase III Influenza-vaccination was allowed. Unfortunately an epidemic of H1N1-flu lead to that almost all patients were vaccinated, many of them in connection with the GAD-vaccinations. In Sweden and Finland the vaccine contained squalen, suspected to influence the immune system towards autoimmunity, and in these two countries there was no efficacy of GAD-treatment, while there was efficacy in other European countries. Patients in Sweden, who did not get the influenza vaccination close to the GAD-treatment, had better effect of the GAD-treatment [73].

9.4. GAD-vaccination and the immune system

In both the Phase IIb and the European Phase III patients treated with two doses of GAD-alum got increasing GADA levels with a maximum after 3 months and then a gradual decrease even if the concentrations of GADA remained significantly higher than in the placebo group. Four doses given in the Phase III trial lead to even higher GADA levels. Increase of GADA had neither relationship to efficacy of the vaccination, nor to adverse events. There was no change of epitopes related to development of Stiff Person Syndrome, but a rather small but significant shift in isotypes with reduced percentage of IgG1 and increased IgG3/IgG4 detected in GAD-alum treated patients[74], in agreement with a Th2 deviation. Spontaneous/non-stimulated and PHA-induced secretion of all cytokines was similar in samples from children receiving GAD-alum and placebo, both before and 15 months after the first injection. Cytokine secretion of IL-5, IL-10, IL-13, IL-17, IFN-γ and TNF-α, but not of IL-6 and IL-12, in response to in vitro stimulation with GAD65 increased in GAD-alum treated patients from baseline to month 15, but a continuous increase was only seen in IL-5, IL-10 and IL-13 while other cytokines remained elevated but at a stable concentration [75]. This indicates that the treatment caused a Th2-
deviation. The immunological effects were long lasting immune responses, as they remained still 48 months after the first injection [75].

As a sign of increase of T-regulatory cells we noticed an increased GAD65-induced expression of FOXP3 and TGF-β at month 15 in cells from GAD-alum treated patients compared to placebo, and the expression of FOXP3 and TGF-β correlated positively in the GAD-alum group but not in the placebo group[77]. Still after 48 months there were clear effects on the immune system suggesting both a Th2 deviation, a decrease of activated T-cells (CD4+CD25+high) but increase of FoxP3-positive regulatory T-cells. Thus, our interpretation is that Diamyd® treatment deviated the immune system towards tolerance against the auto-antigen GAD.

9.5. Other trials with GAD vaccination

Beside the European phase III trial discussed above [73], a similar trial was started a bit later in USA (US Phase III ClinicalTrials.gov Identifier: NCT00751842 ;Jerry Palmer, PI), with the same design. The recruitment was not so fast as initially only patients >16 years old were accepted, and therefore the recruitment had just finished when the negative results of the European Phase III trial was found. This lead to that the American trial was stopped, before it can give any results. In addition another intervention trial in newly-diagnosed Type 1 diabetic patients aged 3-45 years was performed by TrialNet (TrialNet Intervention ClinicalTrials.gov Identifier: NCT00529399). Patients were randomized in a double-blind controlled study into three arms, one with subcutaneous injections of 20 µg GAD65-alum (Diamyd®) at day 1,30 and 90, a second arm with subcutaneous injections of 20 µg GAD65-alum (Diamyd®) at day 1,30 and placebo at day 90, and a third arm with placebo at all time points. The study failed. No effect on C-peptide preservation was found [77]. So far little has been presented from this trial with regard to effects on the immune system. It is difficult to know what the wide age range, variation in ethnic groups, BMI etc meant for the result.

9.6. Ongoing or planned GAD-alum studies

Because of the positive results in the Swedish Phase II study and the positive results in some prespecified subgroups in the European Phase III trial, new studies are planned. As the Phase III trial failed, GAD-alum will be given as part of combination therapy, which hopefully will give a better effect on the disease process. Thus a new pilot trial is just on its way when GAD-alum is combined with Vitamin D, which is supposed to positively influence the dendritic cells, contribute to Th2 deviation, but also influence directly beta cell survival and insulin sensitivity. In addition a third drug, anti-inflammatory, will be given to dampen the inflammation, which might play an important and negative role beside the autoimmune process.

In addition to interventional trials at onset of Type 1 diabetes a pilot trial with the aim to prevent TID is ongoing in southern Sweden. High risk children have been identified as part of the so called DiPiS (Diabetes Prevention in Skåne) study, in which newborn children in the general population have been screened for auto-antibodies. Children positive for GADA, plus at least one more diabetes-related autoantibody, have been treated with either 20 µg GAD65-alum
(Diamyd®) or placebo subcutaneous at day 1 and 30. As the study is not powered for efficacy the main aim is to study safety.

10. DNA vaccines

T-cells respond to antigens presented by antigen presenting cells (APCs). DNA-vaccines can be used to present the antigen instead of delivering intact proteins. A protein encoded by a plasmid DNA can either be produced outside the APCs if the plasmidDNA is administered into a muscle, or the plasmidDNA may be taken up by the APCs where the encoded protein is presented [78]. Proteins encoded by DNA vaccines can induce different types of antigen-specific immune responses, and perhaps also some non-specific reactions.

Most common routes of administration are either intramuscular, which is thought to favour Th1 responses, or intradermal, which is thought to favour Th2 response. For treatment of Type 1 diabetes intradermal injection should be most interesting. Another way of skewing the response towards Th2 may be to co-administer plasmids encoding Th2 cytokines.

Promoters from virus, eg Cytomegalovirus, can be used. Certain sequences seem to stimulate Th1 response and should therefore be avoided in treatment of T1D.

So far DNA-vaccines to create tolerance in autoimmune disease have been tried mainly in experimental animals. Plasmid DNA encoding for proinsulin [79] as well as for the insulin B chain [80] have been used for prevention of diabetes in experimental animals. Injection of plasmidDNA encoding for GAD has been shown effective in preventing diabetes in NOD-mice [81], while similar effect have been seen by combining plasmidDNA encoding for a fusion protein consisting of both GAD, IgG and IL4 [82]. Treatment with a recombinant vaccinia virus expressing GAD ( rVV-GAD65) has also shown to be effective in prevention of autoimmune diabetes in NOD mice by induction of active suppression of effector T-cells [83]. IgG1 antibodies and IL-4 increased and the IgG2 was unchanged, suggesting a Th2 deviation. Before clinical use there are several problems which need to be solved. Correct dosing is necessary as wrong dose might give increased immune response and a more aggressive disease process In addition it is important to be sure that the DNA is not integrated in the host chromosome. Another problem might be production of antibodies against DNA.

11. Beta cell regeneration

The traditional generally accepted view is that when a patient gets Type 1 diabetes there is no longer any capacity of the beta cells to regenerate. However, there are almost no studies on beta cell regeneration in humans. In recent years some studies suggest that the old paradigm may be wrong and that beta cells in fact can regenerate. GLP-1 might stimulate beta cell regeneration and GLP-1 agonist (Exenatide) in combination with monoclonal antibodies interfering with IL-2 ( Daclizumab) was given to patients with longstanding Type 1 diabetes with
some residual insulin secretion, to see whether the treatment could increase C-peptide, but in this study the result was negative [84].

Administration of INGAP (islet neogenesis associated protein) in animals has caused increased beta cell mass and reversal of hyperglycemia, and hopefully INGAP has regenerating capacity in humans. Daily introduction of INGAP or placebo has been tried in a double-blind randomized trial in both Type 1 and Type 2 diabetic patients [85], and it showed increased arginine-stimulated C-peptide during the treatment period, but the effect was very short. Already after 30 days the effect was lost, which does not indicate any influence on beta cell mass as such an effect should have been much longer.

12. Vitamin D and type 1 diabetes

Experimental studies suggest that vitamin D may play a role in the defence against type 1 diabetes as well as type 2 diabetes. Epidemiological data suggest that there is a link between vitamin D deficiency and an increased incidence of Type 1 diabetes. A multinational case-control study and a birth cohort follow-up study from Finland [86] have concluded that vitamin D3 supplementation at birth protects against type 1 diabetes later in life, and a meta-analysis supports similar conclusions [87]. Low serum levels of 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3, calcitriol] has been found in patients with recently diagnosed type 1 diabetes. The protective effects of vitamin D against diabetes are mediated through the regulation of several components such as the immune system and calcium homeostasis. Thus, mechanistic studies show that 1,25(OH)2D3 modulates dendritic cell maturation and facilitates a shift from a Th1 to a Th2 immune response. There is also increasing evidence suggesting that vitamin D also affects beta cells directly thereby rendering them more resistant to cellular stress. There are results indicating that Vitamin D may also improve insulin sensitivity, which in turn decrease beta cell stress.

Vitamin D has been used in patients with recent onset Type 1 diabetes in an effort to preserve residual insulin secretion. However, so far Vitamin D alone has not been efficacious [88, 89]. It seems reasonable to try Vitamin D, both in higher dose, and in combination with other therapy.

13. Anti-inflammatory treatment

In diabetes, both Type 1 and Type 2, there are signs of inflammation, partly related to gluco-toxicity, partly to other traits of the disease. Thus also in Type 1 diabetes there is an inflammatory component in addition to the autoimmune process. IL-1 has been proposed to be of special importance for the destruction of pancreatic beta cells [90], and blocking IL-1 in experimental animals has shown important effects on the disease process. Use of IL-1 inhibitor in Type 1 diabetes has shown reduced serum interleukin 8 (IL-8) levels and reduced CD11b integrin expression on monocytes associated with increased CXCR1 expression. These effects suggest that blocking the IL-1beta pathway results in a reduced ability of mononuclear cells
to go to sites of inflammation. However, there is a great gap between studies in animals and in vitro mechanistic studies, to clinical studies in humans. Recently at the Congress of American Diabetes Association and at the Immunology Diabetes Society the results of two trials blocking the effect of IL-1 in Type 1 diabetes failed. Thus, the use of IL-1r-antagonist showed no effect on preservation of C-peptide or any related clinical parameter[91], and the same was unfortunately the case in another Phase II trial using a IL-1 antagonist, Anakinra [92]. Furthermore blocking IL-1 caused adverse events. Thus, as single therapy using anti-inflammatory drugs is not good enough, but should be tested in combination with other therapies.

14. Future perspectives of immune intervention

No single therapy has shown to be an effective immune intervention in manifest Type 1 diabetes for preservation of residual insulin secretion. As well as successful treatment of childhood leukemia and cancers needed combination of several drugs, it will most probably be necessary to use combination therapies also for Type 1 diabetes. Auto-antigen treatment will probably be part of such future clinical treatment and/or prevention of Type 1 diabetes. Even though GAD-alum so far has not shown any stable efficacy, and Diapep 277 has shown slight efficacy only in adults with good C-peptide preservation, future studies will tell us how to use auto-antigen therapy more effectively, and then in combination with other therapies. It may be so that treatment with GAD may be useful in patients with immune recognition of GAD, and treatment with proinsulin or insulin/insulin chains may be useful in patients whose immune system recognizes these auto-antigens. Furthermore, the effect might be improved by combination therapies with eg Vitamin D, anti-inflammatory drugs, perhaps also in combinations with monoclonal antibodies. New ways of administration may be important and/or DNA-vaccines may be found to be another effective way of creating tolerance against auto-antigens. In spite of recent failures of some immune interventions in clinical trials knowledge is growing and there may soon be a breakthrough.

15. Disclosure

Diamyd Medical was sponsor for the Phase II/III GAD-alum trials and has also given financial support for the investigator-initiated mechanistic studies of this type of therapy. Honorarium for lectures has been received from NovoNordisk, Lilly and SanofiAventis. The author is also member of Advisory Board of LifeScan.

Acknowledgements

In addition to the author the Linköping Diabetes Immune Intervention study group consists of Ass.professor Rosaura Casas, PhD, Stina Axelsson PhD, Mikael Cheramy PhD, and PhD students Mikael Pihl and Linda Åkerman.
We are grateful to excellent technical assistance from Ingela Johansson and Gosia Smolinska, and from research nurses Eva Isacson and AnnMarie Sandström. All pediatricians involved in our studies are also gratefully acknowledged.

Our studies on immune intervention have been generously supported by Barndiabetesfonden (Swedish Child Diabetes Foundation), Swedish Research Council, Research Council of South-east Sweden (FORSS), and the mechanistic studies are supported by Juvenile Diabetes Research Foundation (JDFR).

Author details

Johnny Ludvigsson


References


[18] Baekkeskov S. Immunoreactivity to a 64,000 Mr human islet cell antigen in sera from insulin-dependent diabetes mellitus patients and individuals with abnormal glucose tolerance. Mol Biol Med. 1986 Apr;3(2):137-42


[54] Raz I et al Abstract ADA 2012


[56] Ludvigsson J. Adequate doses of autoantigen administered using the appropriate route may create tolerance and stop autoimmunity. Diabetologia 2009;52 (1):


[70] Agardh C-D, Lynch K, Palmér M, Link K et al. GAD65 vaccination significantly reduces insulin dependence at five years follow-up in a dose escalating study in adult-onset autoimmune diabetes patients. Diabetologia 51 2008;(suppl.1):S230.


[88] Markus Walter, MD,1 Thomas Kaupper, MD,1 Kerstin Adler, PHD,1 Johannes Foersch, 1 Ezio Bonifacio, PHD,2 and Anette-G. Ziegler, No Effect of the 1α,25-Dihydroxyvitamin D3 on β-Cell Residual Function and Insulin Requirement in Adults With New-Onset Type 1 Diabetes. Diabetes Care. 2010 July; 33(7): 1443–1448

[89] Carla Bizzarri, MD,1 Dario Pitocco, MD,2 Nicola Napoli, MD,3 Enrico Di Stasio, MD,2 Daria Maggi, MD,4 Silvia Manfrini, MD,3 Concetta Suraci, MD,4 Maria Gisella Cavallo, MD,5 Marco Cappa, MD,1 Giovanni Ghirlanda, MD,2 Paolo Pozzilli, MD,3 and the IMDIAB Group* No Protective Effect of Calcitriol on β-Cell Function in Recent-Onset Type 1 Diabetes. The IMDIAB XIII trial. Diabetes Care. 2010 September; 33(9): 1962–1963


[91] Greenbaum C. Abstract IDS 2012
